Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PABLO F MORA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1306836168
CMS profile
149702
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$122,305.63

285 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 285 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PABLO F MORA

NPI 1306836168 · CMS profile ID 149702

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 285 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306836168?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PABLO F MORA, NPI 1306836168, CMS profile ID 149702. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 285 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306836168?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PABLO F MORA, NPI 1306836168, CMS profile ID 149702. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 285 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306836168?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PABLO F MORA, NPI 1306836168, CMS profile ID 149702, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 285 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1306836168?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

285 matching records · $122,305.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 285 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 285.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mannkind Corporation $14.2810/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761905 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.7010/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887801305 CMS
Lilly USA, LLC $6.8410/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918272941 CMS
Mannkind Corporation $18.1310/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761903 CMS
SANOFI-AVENTIS U.S. LLC $19.4510/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938846087 CMS
Novo Nordisk Inc $366.0010/17/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899310305 CMS
Novo Nordisk Inc $1,830.0010/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898887211 CMS
Mannkind Corporation $107.4610/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761899 CMS
Mannkind Corporation $20.3010/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761901 CMS
Xeris Pharmaceuticals, Inc. $39.5010/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946488179 CMS
Abbott Laboratories $7.9810/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920438031 CMS
Insulet Corporation $10.4810/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933170169 CMS
Medtronic, Inc. $3.3310/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930650017 CMS
Medtronic, Inc. $14.4310/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930649989 CMS
Xeris Pharmaceuticals, Inc. $18.1410/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946488173 CMS
Novo Nordisk Inc $933.3009/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898545151 CMS
Novo Nordisk Inc $394.1409/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898573063 CMS
Novo Nordisk Inc $499.3209/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898573069 CMS
Novo Nordisk Inc $442.0909/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898887193 CMS
Novo Nordisk Inc $642.4809/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898887203 CMS
Novo Nordisk Inc $6,679.5009/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899434755 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.8209/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930131175 CMS
Abbott Laboratories $9.9609/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920438037 CMS
Mannkind Corporation $57.5009/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761897 CMS
LIFESCAN, INC. $13.8009/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 919444715 CMS
Medtronic, Inc. $19.3709/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930649991 CMS
Mannkind Corporation $17.9609/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761895 CMS
Dexcom, Inc. $3,830.0009/15/2022 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957328093 CMS
Novo Nordisk Inc $22.5109/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898533721 CMS
Novo Nordisk Inc $22.7109/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898533723 CMS
Mannkind Corporation $15.6509/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761893 CMS
Lilly USA, LLC $17.4809/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918244457 CMS
Abbott Laboratories $12.7709/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920438043 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.0908/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887801307 CMS
Insulet Corporation $14.3308/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933164293 CMS
Intuity Medical Inc $14.8608/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905943641 CMS
Lilly USA, LLC $13.5908/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918213061 CMS
Lilly USA, LLC $2.2208/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918217761 CMS
Bayer HealthCare Pharmaceuticals Inc. $18.2208/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930114545 CMS
SANOFI-AVENTIS U.S. LLC $18.0608/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938846065 CMS
Mannkind Corporation $19.6508/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761891 CMS
Medtronic, Inc. $137.5808/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930649987 CMS
Novo Nordisk Inc $16.9208/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899085147 CMS
Dexcom, Inc. $125.0008/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957328109 CMS
Dexcom, Inc. $2,298.0008/18/2022 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957328113 CMS
Insulet Corporation $9.5008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933155799 CMS
Abbott Laboratories $8.8208/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910319925 CMS
Abbott Laboratories $9.8908/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910319927 CMS
Mannkind Corporation $19.5708/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942761889 CMS
Novo Nordisk Inc $17.6608/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899461715 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $336,171.95 439
PY2020 $77,886.46 180
PY2021 $131,164.06 266
PY2022 $122,305.63 285
PY2023 $167,923.03 321
PY2024 $223,720.27 381
PY2025 $276,491.08 492

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $366,051.79 23
PY2024 Recipient $1,563.06 11
PY2024 Principal investigator $153,239.24 24
PY2023 Principal investigator $6,859.80 2
PY2020 Recipient $145.50 1
PY2020 Principal investigator $107,900.03 116
PY2019 Recipient $8,403.48 4
PY2019 Principal investigator $169,054.20 51

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
TEKTON RESEARCH
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534639
Principal investigator 1 ABBVIE INC. $5,814.45 12/31/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202535387
Principal investigator 1 ABBVIE INC. $19,448.10 11/05/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522201
Principal investigator 1 ABBVIE INC. $16,580.70 10/09/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515339
Principal investigator 1 ABBVIE INC. $14,380.20 09/04/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509138
Principal investigator 1 ABBVIE INC. $18,909.45 08/06/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503069
Principal investigator 1 Amgen Inc. $8,025.84 08/01/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246649065
Principal investigator 1 ABBVIE INC. $395.80 07/31/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202500570
Principal investigator 1 ABBVIE INC. $16,046.10 07/02/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494141
Principal investigator 1 SANOFI US SERVICES INC. $23,689.00 07/02/2025 Non-covered Recipient Entity
Tekton Research Inc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226108276
Principal investigator 1 Medtronic, Inc. $1,560.00 06/24/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327470
Principal investigator 1 Medtronic, Inc. $3,500.00 06/17/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327468
Principal investigator 1 ABBVIE INC. $27,603.45 06/03/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488735
Principal investigator 1 Medtronic, Inc. $5,000.00 05/23/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327466
Principal investigator 1 ABBVIE INC. $19,866.60 05/07/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483815
Principal investigator 1 Eli Lilly and Company $127,380.00 04/08/2025 Non-covered Recipient Entity
TEKTON RESEARCH INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187890108
Principal investigator 1 ABBVIE INC. $10,597.50 04/03/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202472819
Principal investigator 1 ABBVIE INC. $12,309.30 03/07/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459134
Principal investigator 1 Amgen Inc. $13,464.70 02/25/2025 Non-covered Recipient Entity
TEKTON RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246649100
Principal investigator 1 Medtronic, Inc. $438.00 02/21/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327464
Principal investigator 1 Medtronic, Inc. $57.00 02/11/2025 Non-covered Recipient Entity
Tekton Research
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327462
Principal investigator 1 ABBVIE INC. $14,385.60 02/06/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448612
Principal investigator 1 ABBVIE INC. $1,080.00 01/02/2025 Non-covered Recipient Entity
TEKTON RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202435031